摘要 |
Disclosed are combination pharmaceutical agents for the treatment of an HCV infection comprising a compound effective to inhibit the function of the HCV NS5A protein and another compound having anti-HCV activity. Compounds which can inhibit the function of the NS5A protein having the structure of formula (I) are described; wherein R, R', R1, R2, and R3 are as defined in the specification. The other compounds having anti-HCV activity are effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH and a nucleoside analog for the treatment of an HCV infection. |
申请人 |
BRISTOL-MYERS SQUIBB COMPANY;COLONNO, RICHARD;LEMM, JULIE;O'BOYLE, DONALD;GAO, MIN;ROMINE, JEFFREY, LEE;MARTIN, SCOTT, W.;SNYDER, LAWRENCE, B.;SERRANO-WU, MICHAEL;DESHPANDE, MILIND;WHITEHOUSE, DARREN |
发明人 |
COLONNO, RICHARD;LEMM, JULIE;O'BOYLE, DONALD;GAO, MIN;ROMINE, JEFFREY, LEE;MARTIN, SCOTT, W.;SNYDER, LAWRENCE, B.;SERRANO-WU, MICHAEL;DESHPANDE, MILIND;WHITEHOUSE, DARREN |